Literature DB >> 10569743

Cytokine profiles of AIDS patients are similar to those of mice with disseminated Cryptococcus neoformans infection.

O Lortholary1, L Improvisi, N Rayhane, F Gray, C Fitting, J M Cavaillon, F Dromer.   

Abstract

Cryptococcosis is an hematogenously disseminated meningoencephalitis during which the relationship between the disease severity and the immune response remains unclear. We thus analyzed, by enzyme-linked immunosorbent assay, proinflammatory (tumor necrosis factor alpha [TNF-alpha] and interleukin-6 [IL-6]) and anti-inflammatory (IL-10) cytokine levels in plasma at the time of diagnosis in 51 AIDS patients with culture-proven cryptococcosis. We used a murine model to determine the correlation between cytokine levels and fungal burden in blood and tissues and the kinetics of the immune response and of the formation of cerebral lesions. In AIDS patients, plasma TNF-alpha and IL-10, but not IL-6, levels were significantly higher in the case of fungemia or disseminated infection than in their absence, whereas the presence of meningitis had no influence on these levels. In mice, none of these cytokines were detected within the first day after inoculation. Later on, TNF-alpha and IL-10, but not IL-6, levels in plasma correlated significantly with the fungal burden in the blood and spleen but not the brain. In the brain, cytokine levels were low compared to those in other compartments, and tissue lesions and a degree of infection similar to those observed in humans were seen, further suggesting the relevance of this experimental model. Thus, AIDS patients with cryptococcosis produce an immune response that reflects the dissemination but not the meningeal involvement. This murine model of disseminated cryptococcosis can be used to investigate the pathophysiology of cryptococcosis and new therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10569743      PMCID: PMC97035          DOI: 10.1128/IAI.67.12.6314-6320.1999

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  39 in total

1.  Purified capsular polysaccharide of Cryptococcus neoformans induces interleukin-10 secretion by human monocytes.

Authors:  A Vecchiarelli; C Retini; C Monari; C Tascini; F Bistoni; T R Kozel
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

2.  Afferent phase production of TNF-alpha is required for the development of protective T cell immunity to Cryptococcus neoformans.

Authors:  G B Huffnagle; G B Toews; M D Burdick; M B Boyd; K S McAllister; R A McDonald; S L Kunkel; R M Strieter
Journal:  J Immunol       Date:  1996-11-15       Impact factor: 5.422

Review 3.  The expanding universe of T-cell subsets: Th1, Th2 and more.

Authors:  T R Mosmann; S Sad
Journal:  Immunol Today       Date:  1996-03

Review 4.  Immunoregulation in cryptococcosis.

Authors:  J W Murphy
Journal:  Immunol Ser       Date:  1989

5.  Role of cytokines in T cell immunity to a pulmonary Cryptococcus neoformans infection.

Authors:  G B Huffnagle
Journal:  Biol Signals       Date:  1996 Jul-Aug

6.  Tumor necrosis factor-inducing activities of Cryptococcus neoformans components.

Authors:  D Delfino; L Cianci; M Migliardo; G Mancuso; V Cusumano; C Corradini; G Teti
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

7.  Enhanced sensitivity of tumor necrosis factor/lymphotoxin-alpha-deficient mice to Cryptococcus neoformans infection despite increased levels of nitrite/nitrate, interferon-gamma, and interleukin-12.

Authors:  N Rayhane; O Lortholary; C Fitting; J Callebert; M Huerre; F Dromer; J M Cavaillon
Journal:  J Infect Dis       Date:  1999-11       Impact factor: 5.226

8.  Biomolecular events involved in anticryptococcal resistance in the brain.

Authors:  E Blasi; R Barluzzi; R Mazzolla; L Pitzurra; M Puliti; S Saleppico; F Bistoni
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

9.  Ingestion of acapsular Cryptococcus neoformans occurs via mannose and beta-glucan receptors, resulting in cytokine production and increased phagocytosis of the encapsulated form.

Authors:  C E Cross; G J Bancroft
Journal:  Infect Immun       Date:  1995-07       Impact factor: 3.441

10.  Human astrocytes inhibit Cryptococcus neoformans growth by a nitric oxide-mediated mechanism.

Authors:  S C Lee; D W Dickson; C F Brosnan; A Casadevall
Journal:  J Exp Med       Date:  1994-07-01       Impact factor: 14.307

View more
  24 in total

1.  Cryptococcal Meningitis in HIV-Infected Patients.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-08       Impact factor: 3.725

2.  Autocrine IL-10 Signaling Promotes Dendritic Cell Type-2 Activation and Persistence of Murine Cryptococcal Lung Infection.

Authors:  Seagal Teitz-Tennenbaum; Steven P Viglianti; Jonathan A Roussey; Stuart M Levitz; Michal A Olszewski; John J Osterholzer
Journal:  J Immunol       Date:  2018-08-10       Impact factor: 5.422

3.  Both Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans.

Authors:  D O Beenhouwer; S Shapiro; M Feldmesser; A Casadevall; M D Scharff
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

4.  Chemokine levels and chemokine receptor expression in the blood and the cerebrospinal fluid of HIV-infected patients with cryptococcal meningitis and cryptococcosis-associated immune reconstitution inflammatory syndrome.

Authors:  Christina C Chang; Saleha Omarjee; Andrew Lim; Tim Spelman; Bernadett I Gosnell; William H Carr; Julian H Elliott; Mohamed-Yunus S Moosa; Thumbi Ndung'u; Martyn A French; Sharon R Lewin
Journal:  J Infect Dis       Date:  2013-08-01       Impact factor: 5.226

5.  Capsule structure changes associated with Cryptococcus neoformans crossing of the blood-brain barrier.

Authors:  Caroline Charlier; Fabrice Chrétien; Marielle Baudrimont; Elodie Mordelet; Olivier Lortholary; Françoise Dromer
Journal:  Am J Pathol       Date:  2005-02       Impact factor: 4.307

6.  Do kinetics of the humoral response to Cryptococcus neoformans proteins during murine cryptococcosis reflect outcome?

Authors:  S Neuville; O Lortholary; F Dromer
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

7.  New insights on the pathogenesis of invasive Cryptococcus neoformans infection.

Authors:  Helene C Eisenman; Arturo Casadevall; Erin E McClelland
Journal:  Curr Infect Dis Rep       Date:  2007-11       Impact factor: 3.725

Review 8.  HIV and co-infections.

Authors:  Christina C Chang; Megan Crane; Jingling Zhou; Michael Mina; Jeffrey J Post; Barbara A Cameron; Andrew R Lloyd; Anthony Jaworowski; Martyn A French; Sharon R Lewin
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

Review 9.  Cryptococcal therapies and drug targets: the old, the new and the promising.

Authors:  Carolina Coelho; Arturo Casadevall
Journal:  Cell Microbiol       Date:  2016-04-08       Impact factor: 3.715

10.  Therapeutic efficacy of a conjugate vaccine containing a peptide mimotope of cryptococcal capsular polysaccharide glucuronoxylomannan.

Authors:  Kausik Datta; Andrew Lees; Liise-anne Pirofski
Journal:  Clin Vaccine Immunol       Date:  2008-06-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.